Aug 9 (Reuters) - The U.S. Food and Drug Administration said on Tuesday certain samples of sitagliptin, a compound in Merck's MRK.N diabetes drug Januvia, were contaminated with a possible carcinogen.

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

After years of battling over the patents on blockbuster diabetes drug Januvia, Merck and its generic rival Viatris are ready to put the case to rest. In a recent filing with the U.S. District Court ...

The savings range from 79% for Januvia, used to manage diabetes, to 38% for Imbruvica, which is used to treat blood cancers. The savings range from 79% for Januvia, used to manage diabetes, to 38% for ...

Expert Rev Endocrinol Metab. 2008;3(6):691-697. Elimination of sitagliptin occurs primarily via renal excretion (79%) and involves active tubular secretion. Sitagliptin is a substrate for human ...

NEW YORK, June 6 (Reuters) - Merck & Co Inc's fast growing diabetes drug Januvia proved effective in helping patients lower blood sugar in combination with Takeda's Actos, and when used along with ...

Merck stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth. The franchise made up 12% of Merck's sales in the first quarter and probably a larger ...